drugset / Trial / NCT00650013

Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

NCT00650013

Phase 1 Completed 23 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's midodrine HCl 5 mg tablets to Roberts ProAmatine® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administration under fed conditions.

Timeline

Start
2002-07
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Midodrine Small molecule 5 mg Oral

Indications

No indication recorded.